Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Geeganage, Chamila ^a   Wilcox, Robert ^b   Bath, Philip M W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; EPTIFIBATIDE; TIROFIBAN; ANTITHROMBOCYTIC AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; BRAIN ISCHEMIA; DRUG COMBINATION; HEART MUSCLE ISCHEMIA; METHODOLOGY; REVIEW; TREATMENT OUTCOME; VASCULAR DISEASE;

BRAIN ISCHEMIA; DRUG THERAPY, COMBINATION; HUMANS; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 77953497679     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-36     Document Type: Article

References (62)

1. Awtry EH, Loscalzo J. Aspirin. Circulation 2000, 101:1206-1218.
2. Cruz-Fernandez JM. Antiplatelet drugs in the treatment of acute coronary syndromes: Focus on cyclooxygenase inhibitors. European Heart J 2004, 3(Supplement 1):123-130.
3. Behan MWH, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad Med J 2004, 80:155-164. 10.1136/pgmj.2003.007062, 1742947, 15016937.
4. Born G, Patrono C. Antiplatelet drugs. Brit J Pharmacol 2006, 147:S241-251.
5. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81-106. 2539220, 8298418, Antiplatelet Trialists' Collaboration.
6. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001, 103(2):201-206.
7. Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324(7329):71-86. 10.1136/bmj.324.7329.71, 64503, 11786451, Antithrombotic Trialists Collaboration.
8. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1-13. 10.1016/S0022-510X(96)00308-5, 8981292.
9. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339. 10.1016/S0140-6736(96)09457-3, 8918275, CAPRIE Steering Committee.
10. Matias-Guiu J, Ferro JM, Sabin JA, Torres F, Jimenez MD, Lago A, Melo T, Tong DC. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: The TACIP study: A randomised, double-blind, multicenter trial. Stroke 2003, 34:840-848. 10.1161/01.STR.0000063141.24491.50, 12649515.
11. Huang Y, Cheng Y, Wu J, Li YX, Hong Z, Shang W, Ding M, Gao X, Fan D, Zeng J, et al. Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention cooperation investigators: Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008, 7:494-499. 10.1016/S1474-4422(08)70094-2, 18456558.
12. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, . Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators The clopidogrel in unstable angina to prevent recurrent events trial investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. New Eng J Med 2001, 345(7):494-502. 10.1056/NEJMoa010746, 11519503, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.
13. Steinhubl SR, Berger PB, Mann JT, Fry ETA, DeLago A, Wilmer C, Topol EJ, . CREDO Investigators Early and sustained dual oral antiplatelet therapy following percutaneous coronary invention: a randomized controlled trial. JAMA 2002, 288(19):2411-2420. 10.1001/jama.288.19.2411, 12435254, CREDO Investigators.
14. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cooks F, Hill KA, Skene AM, , et al. CLARITY-TIMI 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for mocardial infarction with ST-segment elevation. New Eng J Med 2005, 352(12):1179-1189. 10.1056/NEJMoa050522, 15758000, CLARITY-TIMI 28 Investigators.
15. COMMIT (Clopidogrel and Metroprolol in myocardial infarction trial) collaborative group Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366(5):1607-1621. COMMIT (Clopidogrel and Metroprolol in myocardial infarction trial) collaborative group.
16. The ESPRIT Study Group Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006, 367:1665-1673. 10.1016/S0140-6736(06)68734-5, 16714187, The ESPRIT Study Group.
17. National Institute for Health and Clinical Excellence Clopidogrel and modified release dipyridamole in the prevention of occlusive vascular events, 2005. National Institute for Health and Clinical Excellence., http://www.nice.org.uk/nicemedia/pdf/TA090guidance.pdf
18. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, , et al. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology: Guidelines for percutaneous coronary interventions The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005, 26(8):804-847. 10.1093/eurheartj/ehi138, 15769784, Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology: Guidelines for percutaneous coronary interventions.
19. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008, 29(23):2909-2945. 10.1093/eurheartj/ehn416, 19004841.
20. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007, 28(13):1598-1660. 10.1093/eurheartj/ehm161, 17569677.
21. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ, investigators F. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:331-337. 10.1016/S0140-6736(04)16721-4, 15276392.
22. Bhatt DL, Fox KAA, Werner Hacke CB, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, , et al. CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New Eng J Med 2006, 354:1706-1717. 10.1056/NEJMoa060989, 16531616, CHARISMA Investigators.
23. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, , et al. PRoFESS Study Group Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. N Engl J Med 2008, 359:1238-1251. 10.1056/NEJMoa0805002, 2714259, 18753638, PRoFESS Study Group.
24. Singh I, Shafiq N, Pandhi P, Reddy S, Pattanaik S, Sharma Y, Malhotra S. Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol 2009, 68(1):4-13. 10.1111/j.1365-2125.2009.03402.x, 19659998.
25. Bertrand ME, van Belle E. Triple antiplatelet treatment in patients presenting with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2006, 8(Supplement G):G59-63.
26. Higgins JPT, Green S. Cochrane Handbook For Systematic Reviews of Interventions. 2008, London: Wiley Interscience.
27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 2127453, 9310563.
28. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, , et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators Comparison of angioplsty with stenting with or without abciximab, in acute myocardial infarction. New Eng J Med 2002, 346(13):957-66. 10.1056/NEJMoa013404, 11919304, Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators.
29. Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JCA, Gosselink ATM, Dambrink JH, de Boer MJ, Zijlstra F, van't Hof AW. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004, 44(6):1187-1193. 10.1016/j.jacc.2004.06.050, 15364318.
30. Neumann F-J, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M, Schleef M, Seyfarth M, Dirschinger J, Schömig A. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000, 35(4):915-921. 10.1016/S0735-1097(99)00635-X, 10732888.
31. Neumann F-J, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, Kastrati A, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stens in acute myocardial infarction. Circulation 1998, 98:2695-2701.
32. Pretronio AS, Rovai D, Musumeci G, Baglini R, Nardi C, Limbruno U, Palagi C, Volterrani D, Mariani M. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary agioplasty. Eur Heart J 2003, 24:67-76. 10.1016/S0195-668X(02)00324-1, 12559938.
33. Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, Yoon J, Choe KH, Lee SH. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circulation J 2007, 71:1867-1872.
34. Claeys MJ, van der Planken MG, Bosmans JM, Michiels JJ, Vertessen F, van der Goten P, Wuyts FL, Wrints CJ. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for a lycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. Eur Heart J 2005, 26:567-575. 10.1093/eurheartj/ehi071, 15618034.
35. ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000, 356:2037-2044. 10.1016/S0140-6736(00)03400-0, 11145489, ESPRIT Investigators.
36. Eisenberg MJ, Jamal S. Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 2003, 42(1):1-6. 10.1016/S0735-1097(03)00566-7, 12849651.
37. de Queiroz Fernandes A, Veloso HH, Braga De Paiva JM, Filho MW, Vincenzo De Paola AA. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials. Am Heart J 2004, 148(6):937-943. 10.1016/j.ahj.2004.05.047, 15632875.
38. De Luca G, Marino P. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Am J Emerg Med 2009, 27(6):683-690. 10.1016/j.ajem.2008.05.021, 19751625.
39. Jeremias A, Vasu S, Gruberg L, Kastrati A, Stone GW, Brown DL. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. Catheter Cardiovasc Interv 2009, 75:895-902.
40. Sprigg N, Gray LJ, England T, willmot MR, Zhao L, Sare GM, Bath PMW. A randomised controlld trial of triple antiplatelet therapy (Aspirin, Clopidogrel and Dipyridamole) in the secondary prevention of stroke: Safety, tolerability and feasibility (ISRCTN 83673558). PLoS One 2008, 3:e2852. 10.1371/journal.pone.0002852, 2481397, 18682741.
41. Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, Soukhomovskaia O, Ferrari R. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischaemic complications during high-risk coranary angioplasty. J Am Coll Cardiol 2004, 44(1):14-19. 10.1016/j.jacc.2004.03.042, 15234398.
42. Rasoul S, Ottervanger JP, Boer M, Miedema K, Hoorntje JCA, Gosselink M, Zijlsta F, Suryapranata H, Dambrink JE, Hof AWJ. A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA - 2 trial. Eur Heart J 2006, 27:1401-1407. 10.1093/eurheartj/ehl004, 16682384.
43. Kastrati A, Mehilli J, Neumann F, Dotzer F, Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, et al. Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators: Abciximab in patients with acute coranary syndromes undergoing percutaneous coranary intervention after clopidogrel pretreatment. JAMA 2006, 295(13):1531-1538. 10.1001/jama.295.13.joc60034, 16533938.
44. Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, , et al. TIMI Study Group A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: The PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006, 47:2364-2373. 10.1016/j.jacc.2005.12.077, 16781360, TIMI Study Group.
45. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P, . ADMIRAL Investigators Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001, 344(25):1895-1903. 10.1056/NEJM200106213442503, 11419426, ADMIRAL Investigators.
46. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, Parodi G, Fernandez-Pereira C, Moschi G, Bartorelli A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003, 42:1879-1885. 10.1016/j.jacc.2003.07.017, 14662245.
47. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, , et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators Comparison of angioplasty with stenting, with or without abciximab in acute myocardial infarction. N Engl J Med 2002, 346(13):957-966. 10.1056/NEJMoa013404, 11919304, Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators.
48. Ernst NMSKJ, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JCA, Gosselink ATM, Dambrink JE, de Boer M, Zijlstra F, van 't Hof AW. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004, 44:1187-1193. 10.1016/j.jacc.2004.06.050, 15364318.
49. Petronio AS, Rovaib D, Musumecia G, Baglinia R, Nardia C, Limbrunoa U, Palagia C, Volterranic D, Mariania M. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J 2003, 24(1):67-76. 10.1016/S0195-668X(02)00324-1, 12559938.
50. Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, Yoon J, Choe KH, Lee SH. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 2007, 71(12):1867-1872. 10.1253/circj.71.1867, 18037738.
51. Claeys MJ, Planken MGV, Bosmans JM, Michiels JJ, Vertessen F, Goten PVD, Wuytes FL, Vrints CJ. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. Eur Heart J 2005, 26:567-575. 10.1093/eurheartj/ehi071, 15618034.
52. EPISTENT Investigators Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998, 352:87-92. 10.1016/S0140-6736(98)06113-3, 9672272, EPISTENT Investigators.
53. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. New Eng J Med 2004, 350:232-238. 10.1056/NEJMoa031859, 14724302.
54. Hausleiter J, Kastrati A, Mehilli J, Schuhlen H, Pache J, Dotzer F, Glatthor C, Siebert S, Dirschinger J, Schomig A. A randomised trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coranary arteries. J Internal Med 2004, 256:388-397. 10.1111/j.1365-2796.2004.01398.x, 15485474.
55. Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A, . Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators Randomised clinical trial of abciximab in diabetic patients undergoing elective percutaneous coranary interventions after treatement with a high loading dose of clopidogrel. Circulation 2004, 110:3627-3635. 10.1161/01.CIR.0000148956.93631.4D, 15531766, Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators.
56. Bonz AW, Lengenfelder B, Strotmann J, Held S, Turschner O, Harre K, Wacker C, Waller C, Kochsiek N, Meesmann M, Neyses L, et al. Efffects of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin relese in elective percutaneous coranary interventions after petreatment with aspirin and clopidogrel. J Am Coll Cardiol 2002, 40(4):662-668. 10.1016/S0735-1097(02)02014-4, 12204495.
57. Mardikar HM, Hiremath MS, Moliterno DJ, Mathew R, Arora R, Deo D, Hiremath JS, Deshpande NV, Khan A, Joseph J, Mukherjee D. Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study. Am Heart J 2007, 154(2):e341-345.
58. Lee SW, Park S, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, , et al. DECLARE-Long Study Investigators Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007, 100(7):1103-1108. 10.1016/j.amjcard.2007.05.032, 17884371, DECLARE-Long Study Investigators.
59. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus. J Am Coll Cardiol 2008, 51:1181-1187. 10.1016/j.jacc.2007.11.049, 18355656.
60. Min PK, Jung JH, Ko YG, Choi D, Jang Y, Shim WH. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting. Circ J 2007, 71(11):1685-1690. 10.1253/circj.71.1685, 17965485.
61. Douglas JS, Holmes DR, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, , et al. Cilostazol for Restenosis Trial (CREST) Investigators Coronary stent restenosis in patients treated with cilostazol. Circulation 2005, 112(18):2826-2832. 10.1161/CIRCULATIONAHA.104.530097, 16246948, Cilostazol for Restenosis Trial (CREST) Investigators.
62. Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, Shu Q, Tang X. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary interve ntion in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009, 157(4):733-739. 10.1016/j.ahj.2009.01.006, 19332203.